NO20002698L - Cytokinlignende pattedyrpolypeptid 10 - Google Patents

Cytokinlignende pattedyrpolypeptid 10

Info

Publication number
NO20002698L
NO20002698L NO20002698A NO20002698A NO20002698L NO 20002698 L NO20002698 L NO 20002698L NO 20002698 A NO20002698 A NO 20002698A NO 20002698 A NO20002698 A NO 20002698A NO 20002698 L NO20002698 L NO 20002698L
Authority
NO
Norway
Prior art keywords
cytokine
prevention
antibody
treatment
polypeptide
Prior art date
Application number
NO20002698A
Other languages
English (en)
Other versions
NO326561B1 (no
NO20002698D0 (no
Inventor
Darrell C Conklin
Betty A Haldeman
Angelica Grossman
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of NO20002698D0 publication Critical patent/NO20002698D0/no
Publication of NO20002698L publication Critical patent/NO20002698L/no
Publication of NO326561B1 publication Critical patent/NO326561B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
NO20002698A 1997-11-26 2000-05-26 Isolert polynukleotid som koder for et polypeptid med samme biologiske aktivitet som Zcyto10, isolert polypeptid og antistoff. NO326561B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97915697A 1997-11-26 1997-11-26
PCT/US1998/025228 WO1999027103A1 (en) 1997-11-26 1998-11-25 Mammalian cytokine-like polypeptide-10

Publications (3)

Publication Number Publication Date
NO20002698D0 NO20002698D0 (no) 2000-05-26
NO20002698L true NO20002698L (no) 2000-07-20
NO326561B1 NO326561B1 (no) 2009-01-12

Family

ID=25526742

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20002698A NO326561B1 (no) 1997-11-26 2000-05-26 Isolert polynukleotid som koder for et polypeptid med samme biologiske aktivitet som Zcyto10, isolert polypeptid og antistoff.
NO20074516A NO329731B1 (no) 1997-11-26 2007-09-06 Isolert polynukleotid, ekspresjonsvektor, dyrket eukaryot eller prokaryot celle hvori ekspresjonsvektoren er innfort, fremgangsmate for fremstilling av et polypeptid, anvendelse av et isolert polypeptid for fremstilling av et antistoff som spesifikt binder til det isolerte polypeptidet, anvendelse av et polypeptid ved fremstilling av et medikament for a fremme sar-reparasjon av det trakeobronkiale epitel, eller celler som ligger under det trakeobronkiale epitel, eller for behandling av trombocytopeni, samt anvendelse av et antistoff i en diagnostisk analyse for a bestemme det sirkulerende nivaet av loselig Zcyto10-polypeptid

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20074516A NO329731B1 (no) 1997-11-26 2007-09-06 Isolert polynukleotid, ekspresjonsvektor, dyrket eukaryot eller prokaryot celle hvori ekspresjonsvektoren er innfort, fremgangsmate for fremstilling av et polypeptid, anvendelse av et isolert polypeptid for fremstilling av et antistoff som spesifikt binder til det isolerte polypeptidet, anvendelse av et polypeptid ved fremstilling av et medikament for a fremme sar-reparasjon av det trakeobronkiale epitel, eller celler som ligger under det trakeobronkiale epitel, eller for behandling av trombocytopeni, samt anvendelse av et antistoff i en diagnostisk analyse for a bestemme det sirkulerende nivaet av loselig Zcyto10-polypeptid

Country Status (20)

Country Link
EP (3) EP1719780A3 (no)
JP (2) JP5191619B2 (no)
KR (1) KR100574387B1 (no)
CN (2) CN1618969A (no)
AT (1) ATE269902T1 (no)
AU (1) AU739420B2 (no)
BR (1) BR9814904A (no)
CA (1) CA2312000C (no)
CZ (1) CZ300849B6 (no)
DE (1) DE69824755T2 (no)
DK (1) DK1032671T3 (no)
EA (2) EA010741B1 (no)
ES (1) ES2218872T3 (no)
HU (1) HU227703B1 (no)
IL (2) IL136076A0 (no)
NO (2) NO326561B1 (no)
NZ (1) NZ504751A (no)
PL (2) PL198687B1 (no)
UA (2) UA86350C2 (no)
WO (1) WO1999027103A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
AU783473B2 (en) 1999-12-23 2005-10-27 Zymogenetics Inc. Soluble interleukin-20 receptor
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
EP1244708B8 (en) * 1999-12-23 2007-03-07 ZymoGenetics, Inc. Method for treating inflammation
DE60123998T2 (de) 2000-08-08 2007-09-06 Zymogenetics, Inc., Seattle Lösliche zcyctor 11 cytokinrezeptoren
ATE333888T1 (de) 2000-09-15 2006-08-15 Zymogenetics Inc Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
AU2002220076A1 (en) * 2000-10-20 2002-05-06 Zymogenetics Inc. Secreted alpha-helical cytokine-like protein zlmda24
EP1390060A2 (en) * 2001-01-26 2004-02-25 Eli Lilly And Company Use of lp82 to treat body weight disorders
CA2433933A1 (en) * 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
US20040204351A1 (en) * 2001-10-22 2004-10-14 Rowlinson Scott William Soluble proteins that inhibit cytokine signal transduction pathways
CA2467723C (en) 2001-12-17 2011-09-27 Zymogenetics, Inc. Method for treating cervical cancer
JP2007525438A (ja) 2003-03-24 2007-09-06 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
WO2005014028A1 (en) * 2003-08-08 2005-02-17 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
WO2005052001A2 (en) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
DE602004032379D1 (de) 2003-12-19 2011-06-01 Novo Nordisk As Prozessierung von peptiden und proteinen
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
ATE517914T1 (de) 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
AU2005299809B2 (en) 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP1856156A2 (en) 2005-02-08 2007-11-21 ZymoGenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
JP5588970B2 (ja) 2008-05-27 2014-09-10 ダコ・デンマーク・エー／エス ハイブリダイゼーション組成物及び方法
BRPI0914916A2 (pt) 2008-06-30 2015-10-20 Novo Nordisk As anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos
JP5860699B2 (ja) * 2008-10-07 2016-02-16 ナショナル チェン クン ユニバーシティ 骨粗鬆症の治療のためのｉｌ−２０アンタゴニストの使用
US9303287B2 (en) 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
US10662465B2 (en) 2011-09-30 2020-05-26 Agilent Technologies, Inc. Hybridization compositions and methods using formamide
US11118226B2 (en) 2011-10-21 2021-09-14 Agilent Technologies, Inc. Hybridization compositions and methods
EP2823061B1 (en) * 2012-03-05 2018-02-14 Seegene, Inc. Detection of nucleotide variation on target nucleic acid sequence by pto cleavage and extension assay
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
EP3615570A4 (en) 2017-04-25 2021-02-24 LBL Biotechnology Inc. USE OF IL-20 ANTAGONISTS FOR TREATMENT OF EYE DISEASES
WO2021072392A1 (en) * 2019-10-10 2021-04-15 The Research Foundation For The State University Of New York Analgesic and anesthetic peptides and other agents
CN113248567B (zh) * 2021-02-10 2023-02-03 渤海大学 一种苦味受体阻滞肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065396A1 (en) * 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukin-19
EP1244708B8 (en) * 1999-12-23 2007-03-07 ZymoGenetics, Inc. Method for treating inflammation

Also Published As

Publication number Publication date
BR9814904A (pt) 2000-10-03
EP1032671B1 (en) 2004-06-23
PL340755A1 (en) 2001-02-26
DK1032671T3 (da) 2004-10-11
IL136076A0 (en) 2001-05-20
EA200000565A1 (ru) 2000-12-25
JP2001524313A (ja) 2001-12-04
NO326561B1 (no) 2009-01-12
EP1424393A2 (en) 2004-06-02
EP1719780A3 (en) 2006-12-20
IL136076A (en) 2007-12-03
NO20002698D0 (no) 2000-05-26
NZ504751A (en) 2001-10-26
DE69824755T2 (de) 2005-08-04
CZ300849B6 (cs) 2009-08-26
EP1719780A2 (en) 2006-11-08
ES2218872T3 (es) 2004-11-16
EP1032671A1 (en) 2000-09-06
CN1618969A (zh) 2005-05-25
EA200401501A1 (ru) 2006-02-24
CZ20001910A3 (cs) 2000-11-15
JP2010187698A (ja) 2010-09-02
PL195304B1 (pl) 2007-08-31
UA73275C2 (en) 2005-07-15
HUP0100436A3 (en) 2003-08-28
AU1607799A (en) 1999-06-15
ATE269902T1 (de) 2004-07-15
EA005581B1 (ru) 2005-04-28
JP5331054B2 (ja) 2013-10-30
CN1247780C (zh) 2006-03-29
AU739420B2 (en) 2001-10-11
EP1424393A3 (en) 2004-06-09
CN1282372A (zh) 2001-01-31
NO20074516L (no) 2000-07-20
JP5191619B2 (ja) 2013-05-08
KR100574387B1 (ko) 2006-04-27
CA2312000C (en) 2013-03-26
CA2312000A1 (en) 1999-06-03
HU227703B1 (en) 2011-12-28
KR20010032490A (ko) 2001-04-25
PL198687B1 (pl) 2008-07-31
EA010741B1 (ru) 2008-10-30
DE69824755D1 (de) 2004-07-29
UA86350C2 (en) 2009-04-27
NO329731B1 (no) 2010-12-13
HUP0100436A2 (hu) 2001-06-28
WO1999027103A1 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
DK1032671T3 (da) Mammalt cytokin-lignende polypeptid-10
DE69634726D1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
IL210455A (en) A polypeptide for reducing mammalian signaling 13il, and using a polypeptide to produce a drug for up-regulating gene expression 2ra13-il in mammals
DE69828193D1 (de) Hyaluronan synthase gen und seine verwendung
EP1466925A4 (en) ANTIBODIES TO THE FIBROBLAST GROWTH FACTOR 23
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
IL141869A0 (en) Mammalian transforming growth factor beta-9 (ztgfss9)
EP1501936A4 (en) PROTEIN FAMILY OF CYTOKINE
ATE534742T1 (de) Polypeptide und nukleinsäuren von phorphorymonas gingivalis
DE69120626D1 (de) Polypeptid
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
ATE229983T1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
DE59710091D1 (de) Von Kaposi-sarkom assoziiertem Herpes-Virus (KSHV, HHV-8) kodiertes Polypeptid und dessen Verwendung in Diagnostik und Therapie
ATE366810T1 (de) Menschliche p51-gene und deren genprodukte
ATE251640T1 (de) Neues chondrozytprotein
KR950704352A (ko) 테라포시데 아포노펠마로부터의 칼슘 통로 차단 폴리펩티드(calcium channel blocking polypeptides from theraphosidae aphonopelma)
NZ505350A (en) DNA encoding a tumour antigen peptide (43 kDa) for diagnosis or treatment of tumours
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
KR930019827A (ko) 신규 폴리펩티드 및 이를 암호하는 dna
MX9504057A (es) Proteina que tiene actividad tpo.
NZ606260A (en) Novel polypeptides involved in immune response
WO1999060117A3 (fr) Polypeptide prax-1

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees